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Background. Development of high avidity, broadly neutralizing antibodies (Abs) is a priority after vaccination against rapidly 
evolving, widely disseminated viruses like human norovirus. After vaccination with a multivalent GI.1 and GII.4c norovirus virus-
like particle (VLP) vaccine candidate adjuvanted with alum and monophosphoryl lipid A (MPL), blockade Ab titers peaked early, 
with no increase in titer following a second vaccine dose.
Methods. Blockade Ab relative avidity was evaluated by measuring the slope of blockade Ab neutralization curves.
Results. Blockade Ab avidity to the GI.1 vaccine component peaked at day 35 (7 days after dose 2). Avidities to heterotypic 
genogroup I VLPs were not sustained at day 35 after vaccination or GI.1 infection, as measured from archived sera. Only secre-
tor-positive participants maintained high avidity blockade Ab to GI.1 at day 180. Avidity to the GII.4c vaccine component peaked at 
day 7, remained elevated through day 180, and was not secretor dependent. Avidity to an immunologically novel GII.4 strain VLP 
correlated with preexisting Ab titer to an ancestral strain Epitope A.
Conclusions. Host genetics and pre-exposure history shape norovirus vaccine Ab responses, including blockade Ab avidity. 
Avidity of potentially neutralizing Ab may be an important metric for evaluating vaccine responses to highly penetrant viruses with 
cross-reactive serotypes.
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Human noroviruses (NoVs) are the leading cause of acute viral 
gastroenteritis, resulting in substantial morbidity and financial 
burdens [1–4]. Development of an effective vaccine would partic-
ularly benefit vulnerable populations, including young children, 
immunocompromised persons, and older adults, who are most 
likely to suffer severe NoV illness and the consequences thereof. 
There are several obstacles to the development of a successful 
NoV vaccine—extensive genetic diversity; lack of a readily repro-
ducible cell culture system (although progress is being made [5, 
6]) or small animal model [7]; antigenic drift, particularly within 
the predominant genotype (GII.4) [8, 9]; and the unknown effect 
of pre-exposure history [10]. In addition, methods to assess vac-
cine-induced immune responses to capture potentially important 
correlates of protection remain to be established.
Exposure to multiple NoV genotypes results in cross-react-
ing antibody (Ab), making preexisting enzyme immunoassay 
(EIA)–reactive Ab an imprecise predictor of protection from 
infection [10, 11] because preexisting serum Ab levels in pre-
viously exposed individuals could limit the magnitude of the 
fold rise in titer [12, 13]. The blockade assay, a surrogate neu-
tralization assay that measures the ability of Abs to block bind-
ing of NoV virus-like particles (VLPs) to carbohydrate ligands 
[14–16], is more sensitive to epitope variation and is a proposed 
correlate of immune protection [17–19]. In the context of vac-
cination, blockade Ab titers reach a plateau [20, 21]. This ceil-
ing effect may contribute to the reported lack of titer increase 
in previously exposed individuals after a second dose of NoV 
vaccine 28  days after the first vaccine dose, as has also been 
described for some subjects with preexisting influenza hemag-
glutination inhibition assay (HAI) titer [12, 22].
Neutralization depends on Ab affinity (strength of the Ab–
antigen molecular interaction at a concentration) and accessibil-
ity of epitopes [23]. In polyclonal sera, the strength of all antigen 
interactions is called avidity. Avidity may provide an informa-
tive metric for evaluating vaccine responses to antigens with 
high population exposure where the polyclonal serum response 
includes specific and cross-reactive non-neutralizing Abs [12, 
22]. Previous studies using classical avidity assays that rely on 
chaotropic reagents to disrupt antigen–Ab interactions found 
increases in immunoglobulin G and immunoglobulin A avidity 
by 2 weeks after NoV infection [24, 25]. Neutralizing Abs com-
prise only a fraction of the total reactive serum Ab repertoire and 
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are characterized for potency by sigmoidal dose–response curves 
that define neutralization as a function of Ab concentration. 
Neutralizing Abs typically have extensive somatic hypermutation 
of complementarity-determining regions and increased affinity 
for the antigen. Both Ab affinity (avidity for polyclonal sera) and 
access to neutralizing epitopes on the antigen are reflected in the 
slope at the half maximal effective concentration EC50 titer (Hill 
slope) of the dose–response curve. Higher value (steeper) slope 
indicates higher avidity from either higher affinity Ab (somatic 
hypermutation of the binding sites) [26] or better epitope access 
[27] and, subsequently, increased likelihood of attaining neutral-
ization. In the studies included here, the amount of antigen (epi-
topes) and Ab is held constant between VLPs, allowing changes 
in slope to indicate changes in relative avidity. Slope analysis may 
be preferable to urea treatment for measurement of avidity of 
neutralizing Abs because urea preferentially disassociates Ab 
bound to discontinuous epitopes [28]. Recent studies of human 
immunodeficiency virus broadly neutralizing Abs and retroviral 
drugs have found the neutralization curve slope to be more pre-
dictive of clinical outcome than EC50 titer alone [29, 30].
Several NoV vaccine candidates are in development [4]. 
The most advanced, a multivalent VLP candidate vaccine, is 
currently in phase IIb clinical trials [20, 31, 32]. The vaccine 
includes a genogroup I prototype VLP (GI.1) and a genogroup 
II GII.4 consensus VLP (GII.4c). In initial studies, 4 dosages 
(5/5, 15/15, 50/50, and 150/150 µg GI.1/GII.4c VLP) of the mul-
tivalent vaccine elicited similar reactogenicity and EIA-reactive 
serum Ab responses in adults [31]. Peak reactive IgG was 
detected at day 7, indicating that the Ab responses are second-
ary responses resulting from past NoV exposures. In this study, 
we evaluated relative avidity of blockade Ab using the slope of 
the blockade curve as a potential metric for vaccine Ab response 
after NoV vaccination.
MATERIALS AND METHODS
Ethics Statement
This study used coded human samples under University of 
North Carolina Institutional Review Board exemption approval 
number 14–2129. Original samples were collected by Takeda 
Vaccines Inc under approval by institutional review boards at 
Saint Louis University School of Medicine, Saint Louis, Missouri; 
University of Rochester School of Medicine and Dentistry, 
Rochester, New York; and the Navy Medical Research Center, 
Silver Springs, Maryland (registered on Clinical Trials.gov, NCT 
01168401). All participants provided written informed consent.
Serum Samples
Serum was collected from 29 participants in a NoV vaccine 
dose–response study (cohorts A2–A4 [31]) conducted by 
Takeda Vaccines Inc, Deerfield, Illinois. Participants were vac-
cinated in January 2011 with an intramuscular injection of GI.1 
and GII.4c VLPs adjuvanted with 3-O-deacyl monophosphoryl 
lipid A  (MPL, GlaxoSmithKline) and aluminum hydroxide 
(Brenntag Biosector, Denmark) on day 0 (dose 1)  and again 
on day 28 (dose 2). Ten subjects each received 15  µg of VLP 
(subgroup A2) and 50 µg of VLP (subgroup A3), and 9 subjects 
received a dose of 150 µg VLP (subgroup A4). Demographics of 
the complete study population and subgroups A2–A4 are avail-
able [21, 31]. Two participants, 1 each in the 15-µg and 150-µg 
dose groups, did not provide sera past day 21 and were excluded 
from this study. One participant in the 50-µg VLP group did not 
provide day 180 serum. All other serum samples collected were 
included in the analyses unless the sample volume was depleted 
(50 µg/VLP dose sera for GII.4.2012 avidity measurements on 
days 7 [n = 7] and 180 [n = 8]). The secretor status of sample 
donors was determined previously [31]. Additionally, archived 
sera from 10 secretor-positive subjects experimentally infected 
with GI.1 in a separate study [24, 33] were evaluated. One day 
35 sample was not available for analysis.
Blockade Antibody Titer and Relative Avidity
Blockade Ab data were fit using sigmoidal dose–response anal-
ysis of nonlinear data in GraphPad Prism 6.02, and the mean 
EC50 and slope of the curve with 95% confidence intervals (95% 
CIs) were determined [21]. Sera that did not block 50% of bind-
ing at the highest concentration tested were assigned an EC50 of 
20. By definition, these samples would not have any Hill slope 
(no EC50) and were assigned a slope (relative avidity) of 0.1 for 
statistical comparison.
Statistical Analysis
Statistical analyses were done using GraphPad Prism 6.02. 
Geometric mean titer (GMT), and geometric mean fold rise 
(GMFR), slope (avidity), EC50 titers, and 95% confidence inter-
vals were determined from dose–response sigmoidal curve fits. 
Endpoints were compared within group but between days or 
doses by Wilcoxon signed rank test (Wilcoxon) for repeated 
measurements without normal distribution [34]. Association 
between secretor-status and responses was evaluated with 
Fisher’s exact test. Correlations between day 0 serum titer to 
GII.4.1997 Epitope A  and day 180 avidity to GII.4.2012 and 
between blockade Ab slope and IgG/IgA urea-determined avid-
ity were assessed with the Spearman rank correlation. P < .05 
was considered significant.
RESULTS
In the parent study, human NoV vaccination resulted in 
broadly reactive serum blockade Ab responses that peaked 
in titer 7 days after 1 dose with little or no increase in titer 
after a booster vaccination at day 28 [21, 31]. To evaluate 
whether immunization boosted blockade Ab avidity in 
the absence of an increase in blockade Ab titer, we com-
pared the Ab titer (reported previously in [21] for the 50–
µg/VLP dose) and the relative Ab avidity, as measured by 
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the EC50 and slope of the blockade curve of time-ordered 
serum samples collected from NoV vaccinated participants 
dosed with 150, 50, or 15 µg of GI.1 and GII.4c VLP adju-
vanted with alum and MPL [31]. Blockade Ab avidity was 
not dose dependent at any day for GI.1 (Wilcoxon). For all 
doses combined, GI.1 blockade Ab avidity increased at day 7 
(GMFR = 12.2; 95% CI = 9.2–16.1), remained consistent at 
day 21, and then at day 35 (7 days after dose 2) rose (GMFR 
of 2.1, 95% CI = 1.3–3.4 compared with day 7; GMFR = 26.0, 
95% CI  =  17.5–38.6 compared with day 0)  (Wilcoxon) 
(Figure  1). At day 180, avidity declined below day 7 levels 
but remained elevated above day 0 levels. Comparing the 
individual dose groups, titers peaked at day 7 and gradually 
declined through day 180 (Supplementary Figure  1A–C), 
whereas avidity improved at day 35 compared with day 7 for 
the 150– and 50–µg/VLP doses (Wilcoxon) (Supplementary 
Figure 1D–F). Elevated avidity was maintained at day 180 in 
the 150-µg group but in only select participants in the 15- 
and 50-µg dose groups (Wilcoxon). Although short-term Ab 
response to the VLP vaccine was not dependent on secre-
tor phenotype, secretor-positive participants (closed circles, 
Supplementary Figure 1, [21]) of any blood type were more 
likely to maintain GI.1 high avidity Ab at day 180, compared 
with secretor-negative participants (P = .02, Fisher’s). None 
of the 4 secretor-negative subjects had blockade Ab titer to 
GI.1 at day 180, regardless of vaccine dose.
Antigenic cartography analyses of blockade Ab cross-reactiv-
ity patterns to other GI NoV VLPs not included in the vaccine 
among the 50-µg VLP dose group suggested that the blockade 
Ab response to the GI.1 vaccine component was predominately 
strain specific [21]. In agreement, avidity to GI.1, GI.3, and GI.4 
was similar at day 0 and rose above baseline for GI.1 (GMFR 
15.5; 95% CI = 10.4–23.0) and GI.3 (GMFR = 5.6; 95% CI = 2.3–
13.5) at day 7 (Figure 2). Avidity to only GI.1 increased at day 35 
(GMFR = 37.3; 95% CI = 30.3–45.9; Wilcoxon), whereas avidity 
to GI.3 and GI.4 retuned to baseline levels. Avidities were simi-
lar between all GI VLPs at day 180.
To determine whether the patterns of strain-specific 
GI blockade Ab titer and avidity responses to vaccination 
mimic the patterns after GI.1 natural infection, we retested 
archived serum samples collected from secretor-positive sub-
jects experimentally infected with GI.1 (Figure  3) [24, 33]. 
When tested under similar assay conditions, subjects infected 
with GI.1 developed increased homotypic blockade Ab titer 
at day 14 (GMFR = 12.2; 95% CI = 4.6–32.0). Elevated titer 
was maintained at day 35 (GMFR = 5.5; 95% CI = 2.3–13.0; 
Wilcoxon) after challenge. Similarly, GI.1 blockade Ab avidity 
was elevated at day 14 (GMFR = 5.4; 95% CI = 2.2–13.0) and 
sustained at least through day 35 (GMFR = 6.3; 95% CI = 2.2–
17.8; Wilcoxon) (Figure  3A). Previously-determined total 
GI.1 Ab avidity determined by urea EIA [24] correlated with 
blockade Ab slope for IgA (Spearman r = 0.54; P = .0006) and 
IgG (Spearman r  =  0.58; P  =  .0002). At day 14 heterotypic 
blockade Ab titers to GI.3 (GMFR = 5.1; 95% CI = 1.6–16.0) 
(Figure  3B) and GI.4 (GMFR  =  17.6; 95% CI  =  5.5–56.2) 
increased. Titer to GI.4 remained elevated at day 35 
(GMFR  =  5.3; 95% CI  =  1.8–15.7; Wilcoxon) (Figure  3C). 
Blockade Ab avidity did not change from baseline levels for 
either GI.3 or GI.4 at any time point. These data indicate that 
cross-GI blockade Ab titer and avidity response patterns to 
vaccination with GI.1 VLP are similar to the response pat-
terns to GI.1 strain infection.
Comparing the individual dosage groups, blockade Ab titers 
to GII.4c peaked at day 7 and gradually declined through day 
180 (Supplementary Figure 2A–C). However, avidity improved 
only on days 7, 21, and 35 for the 15– and 50–µg/VLP dose 
group (Wilcoxon) and was unchanged over time in the 150–µg/
VLP dose group (Supplementary Figure  2D–F). For all doses 
combined, GII.4c blockade Ab titers peaked at day 7 after dose 
1 (GMFR = 16.4; 95% CI = 7.5–35.6; Wilcoxon) and generally 
remained consistent through day 35 before declining at day 
180 (Figure 4). Responses were generally similar between dose 
groups (Wilcoxon). After vaccination, GII.4c blockade Ab avid-
ity rose at day 7 (GMFR = 4.9; 95% CI = 2.7–8.8; Wilcoxon), 
reaching a plateau through day 180. At day 0, blockade Ab 
avidity to GII.4c was already measureable, possibly limiting 
the effect of vaccination when measured by a change compared 
with day 0. Consistent with infection and in vitro binding data 
[35–37], GII.4c Ab avidity at day 180 was not associated with 
secretor phenotype (Supplementary Figure 2D–F), although the 
number of secretor-negative participants is low (n = 4). There 
was also no association between participant blood type and Ab 
avidity at day 180.
Figure 1. Blockade antibody (Ab) relative avidity, but not titer, to the GI.1 vaccine 
component improves over time. Geometric mean blockade Ab titer (GMT, black) and 
avidity (gray) were determined from GI.1 blockade Ab dose–response curves for 
each participant dosed with 15, 50 or 150 µg/virus-like particle (VLP) before vacci-
nation (day 0), 7 days after first dose (day 7), 21 days after first dose (day 21), 7 days 
after second vaccine dose (day 35), and 180 days after first dose (day 180). Bars 
represent the GMT, and whiskers represent the 95% confidence interval. Dotted 
lines equal the assay limits of detection. Abbreviations:*, Significant increase from 
day 0; #, Significant increase from day 7.
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Among the 50-μg dosage group, on days 0 and 7 blockade 
Ab avidities were similar between GII.4c, and previous pan-
demic strain VLPs GII.4.1997, 2002, and 2006b (Figure 5). At 
day 35, blockade Ab avidity between GII.4c and GII.4.1997 
remained similar to each other and greater than the avid-
ity for 2002 and 2006b (Wilcoxon), establishing avidity as an 
additional metric identifying the association between GII.4c 
and GII.4.1997 Ab response after vaccination. At day 180, 
GII.4.2006b blockade Ab avidity was lower compared with the 
other GII.4 VLPs, which were similar to each other (Figure 5). 
Thus, blockade Ab relative avidity measurements indicate 
vaccination primarily elicits a memory blockade Ab response 
to cross-reactive GII.4 epitopes. For GII.4.2012, a strain that 
emerged about 1 year after study sample collection was com-
pleted, Ab avidity was higher on day 7 and 21 compared with 
day 0 (Wilcoxon) (Figure  6). Increased blockade Ab avidity 
was not sustained long-term. However, 3 of 8 participants 
maintained high avidity blockade Ab responses to the novel 
GII.4 VLP at day 180. These 3 participants were secretor pos-
itive and had preexisting blockade-of-binding (BOB) titer to 
Epitope A of GII.4.1997. Preexisting BOB titer to Epitope A of 
GII.4.1997, but not to Epitope A of GII.4.2006b or Epitope F of 
either strain, correlated with avidity to GII.4.2012 at day 180 
(Spearman r = 0.84; P = .02), further implicating host genetics 
and subsequent strain exposure history as key determinants of 
vaccine response.
DISCUSSION
In this article, we focused on relative avidity of the blockade 
Ab response across NoV strain, vaccine dose, and host secretor 
status. Using the slope of the Ab blockade curve, as opposed 
to urea treatment of total serum, allows specific assessment of 
the avidity of the fraction of total serum immunoglobulin that 
potentially blocks the virus binding to its cellular receptor. This 
approach eliminates the effect of cross-reactive serum Ab as 
well as the inherent skewing of urea-based EIA methodologies 
toward Abs to linear epitopes, which confound classical avidity 
measurements of serum [28].
Our analyses revealed key differences in avidity responses 
between the vaccine components. Importantly, blockade Ab 
avidity to GI.1 increased over time, largely in a strain-spe-
cific pattern. This suggests that memory B cells likely under-
went further somatic hypermutation and refinement for the 
GI.1 immunogen, either as a result of time or the second 
vaccine dose. This would explain the increased avidity to 
GI.1 and the reported decrease in blockade Ab titer to GI.3 
and GI.4 because these responses likely can be attributed to 
cross-GI Ab epitopes that were selected against during fur-
ther GI.1 affinity maturation. The lack of change in avidity to 
GI.3 or GI.4 after the second dose of vaccine or after natural 
infection supports this hypothesis. If this is indeed the case, 
then vaccination with a different GI genotype VLP at the sec-
ond dose may have different effects, preferentially selecting 
for expansion of Ab to conserved GI epitopes, improving 
the avidity to multiple GI strains instead of driving a largely 
GI.1-specific blockade Ab response. Further research is nec-
essary to determine whether this pattern of Ab expansion 
exists and what the implication may be for infection and 
vaccination.
Norovirus susceptibility is mediated at least in part by the 
expression pattern of histoblood group antigens (HBGAs) on 
mucosal surfaces. Individuals who do not express the FUT2 
Figure 2. Vaccine serum blockade antibody (Ab) relative avidity increases specifically to the GI.1 vaccine component compared with other GI virus-like particles (VLPs) in 
the 50–µg/VLP dose group. Mean slope was determined from GI.1, GI.3, and GI.4 blockade Ab dose–response curves for each secretor-positive (closed marker) and secre-
tor-negative (open marker) participant in the 50–µg/VLP dose group before vaccination (day 0), 7 days after first dose (day 7), 7 days after second vaccine dose (day 35), and 
180 days after first dose (day 180). Bars represent the geometric mean titer (GMT), and whiskers represent the 95% confidence interval. Dotted line equals the assay limit of 
detection. Abbreviations: *, Significant increase from day 0; #, Significantly different from GI.1 avidity at the same day.
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gene and as a result have low levels of HBGAs expression (non-
secretors) are genetically resistant to GI.1 infection/illness [10]. 
Secretor-negative status does not protect against infection with 
all strains or even with some other GI strains [38] and, subse-
quently, secretor-negative individuals may have serum Ab that 
cross-reacts with GI.1 by EIA [10]. Blockade Ab titer in response 
to vaccination was independent of secretor status in the 50–µg/
VLP dose group [21], however, none of the secretor-negative 
participants maintained high-avidity GI.1 blockade Ab at day 
180. These data support the hypothesis that, mechanistically, 
vaccination of previously exposed individuals activates preexist-
ing memory B cells that are the result of previous exposure and 
illustrate how the dosing regimen and host genetics will impact 
vaccine outcomes.
In comparison with the genetic restriction of GI.1 infection, 
GII.4 strains bind to a diverse set of HBGAs and infect both 
secretor-positive and, to a lesser degree, secretor-negative indi-
viduals [35–37, 39]. Further, successive GII.4 strains circulate 
globally, causing both endemic and pandemic levels of disease 
[39, 40]. These factors keep population exposure to GII.4 strains 
high and maintain herd immunity to ancestral strains. This 
repeat exposure of similar antigen is reflected in the focusing 
GII.4 avidity measurements [41]. If a serum sample had a block-
ade Ab titer above the limit of detection, the avidity remained 
relatively consistent across time and GII.4 VLP. These data 
suggest that the first dose of multivalent vaccine in previously 
exposed individuals activates preexisting memory B cells to 
epitopes conserved across multiple GII.4 strains and accounts 
for the broad GII blockade Ab response reported and mecha-
nistically mirrors the GI VLP response at early time points. In 
contrast with the GI.1 response, the GII.4 avidity response was 
not specific for GII.4c. At day 35, GII.4c avidities were similar to 
GII.4.1997 and greater than GII.4.2002 and 2006b, supporting 
antigenic cartography and epitope-specific BOB assays indicat-
ing that early GII.4 strain exposure may shape subsequent GII.4 
blockade Ab responses [21].
Figure 3. GI.1 infection induces broad GI blockade antibody (Ab) titer response 
but only GI.1-specific increases in blockade Ab relative avidity. Geometric mean 
blockade Ab titer EC50 (black) and avidity (gray) were determined from GI.1 (A), GI.3 
(B), and GI.4 (C) blockade Ab dose–response curves on day 0, 4, 14, and 35 after 
GI.1 infection. Bars represent the geometric mean titer (GMT), and whiskers repre-
sent the 95% confidence interval. Dotted line equals the limit of detection for both 
assays. Abbreviation: *, Significant increase from day 0.
Figure 4. Blockade antibody (Ab) relative avidity to the GII.4c vaccine component 
peaks early and is sustained through day 180. Mean EC50 titer (black) and rela-
tive avidity (gray) were determined from GII.4c blockade Ab dose–response curves 
for each participant dosed with 150, 50, and 15 µg/virus-like particle (VLP) before 
vaccination (day 0), 7  days after first dose (day 7), 21  days after first dose (day 
21), 7 days after second vaccine dose (day 35), and 180 days after first dose (day 
180). Bars represent the geometric mean titer (GMT), and whiskers represent the 
95% confidence interval. Dotted line equals assay limits of detection. Abbreviation: 
*, Significant increase from day 0.
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Elucidating epitopes targeted by neutralizing Abs provides a 
framework for vaccine design and a metric for evaluating pro-
tective immune responses with fewer clinical trials. Of particular 
interest are epitopes for broadly neutralizing Abs that provide 
protection from infection across strains [29, 42, 43]. Our studies 
with NoV-vaccinated individuals did not include virus challenge 
after immunization; therefore protection cannot be assessed, 
but multivalent vaccination did induce broad blockade Ab 
responses, a proposed correlate of protection from infection, 
that cross-reacted with novel GII.4 VLPs representing emergent 
variants for which the population was immunologically naive 
[21]. These data suggest that the vaccine may provide cross-pro-
tection to emergent GII.4 strains. In support, avidity to the novel 
GII.4.2012 VLP followed the same pattern as the avidity to the 
other GII.4 VLPs that had widely circulated in the general pop-
ulation of the United States. However, as described for the GI.1 
response, only a subset of individuals sustained high avidity Ab 
to day 180. The participants that did sustain long-term responses 
were all secretor-positive and had detectable high-avidity block-
ade Ab to the immunodominant Epitope A of GII.4.1997, the 
first recognized pandemic NoV strain, further indicating that 
vaccination is driving a cross-reactive memory Ab response to 
the GII.4c vaccine component and identifying Epitope A  as a 
possible primary driver of the vaccine response.
The chief limitation of this study is the lack of testing of the 
association of increased Ab avidity and protection from NoV 
infection/illness in a biological model. Use of a biochemical 
assay to measure potential neutralizing Ab titers and avidities 
incurs confounding variables. Incubation at room tempera-
ture, as reported here, favors binding of Abs to surface-exposed 
residues with strong blocking potential and steep blockade 
curve slopes. In comparison, incubation at 37°C likely favors 
binding of Ab to surface-exposed epitopes, occluded epitopes, 
and cross-reactive-lower avidity Abs [27, 44, 45]. Subsequent 
additional Ab binding increases the blockade Ab titer (EC50) 
but decreases the slope of the curve because less potent Abs 
contribute to the blockade activity. Extended incubation times 
may partially compensate for the effects of decreased incuba-
tion temperatures [46]. The effects of incubation temperatures 
Figure 6. Select secretor-positive participants maintain blockade antibody (Ab) 
relative avidity to novel antigen GII.4.2012 virus-like particles (VLPs) in the 50–µg/
VLP dose group. Mean slope was determined from GII.4.2012 blockade antibody 
dose–response curves for each secretor-positive (closed circles) and secretor-nega-
tive (open circles) participant in the 50–µg/VLP dose group before vaccination (day 
0), 7 days after first dose (day 7), 21 days after first dose (day 21), 7 days after 
second vaccine dose (day 35), and 180 days after first dose (day 180). Bars represent 
the geometric mean titer (GMT), and whiskers represent the 95% confidence inter-
vals. Dotted line equals the assay limit of detection. Abbreviation: *, Significant 
increase from day 0.
Figure 5. Vaccination preferentially increases relative avidity to GII.4c and GII.4.1997 in the 50–µg/virus-like particle (VLP) dose group. Mean slope was determined from 
GII.4c, GII.4.1997, GII.4.2002, and GII.4.2006b blockade antibody (Ab) dose–response curves for each secretor-positive (closed circles) and secretor-negative (open circles) 
participant in the 50–µg/VLP dose group before vaccination (day 0), 7 days after first dose (day 7), 21 days after first dose (day 21), 7 days after second vaccine dose (day 35), 
and 180 days after first dose (day 180). Bars represent the geometric mean titer (GMT), and whiskers represent the 95% confidence interval. Dotted line equals the assay limit 
of detection. Abbreviations: *, Significant increase from day 0; #, Significantly different from GII.4c avidity at the same day.
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and times on Ab reactivity and avidity measurements apply 
to both the human test antiserum and the rabbit antiserum 
used to detect the VLP bound to the carbohydrate ligand, 
although this concern is mitigated in part by the use of lim-
iting amounts of VLP and rabbit antiserum in these assays. 
Further, between-VLP dynamics regulating epitope access 
were assumed to be negligible, and this may not be the case, 
especially for the GII.4c VLP, the only VLP in the study not 
made in a mammalian expression system [27]. Despite these 
challenges, we were able to identify novel outcomes of NoV 
vaccination associating a genetic phenotype with the likeli-
hood of maintaining long-term (180  days), high-quality Ab 
responses.
Additional studies including virus challenges with and with-
out prior vaccination are needed to further our understanding 
of the mechanistic correlates to protection from NoV infection/
illness as well as the long-term effects of dosing regimens and 
adjuvant usage. Inclusion of blockade Ab avidity as a study end-
point may clarify the impact of host genetics and preexisting 
immunity for not only NoV but also other highly penetrant, 
antigenically diverse viruses, including human immunodefi-
ciency virus, influenza, and dengue.
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